New Year Debut Of Another Biosimilar Humira In India

 
• By Anju Ghangurde

AbbVie may have managed to push back direct biosimilar competition to Humira (adalimumab) in the US by a few years, but 2018 has begun with the launch of yet another biosimilar of the blockbuster biologic in India. Hetero, the latest entrant, expects to maintain pricing parity with its peers on the domestic market.

Leadership
HETERO HAS INTRODUCED ITS BIOSIMILAR HUMIRA IN INDIA

More from Business

More from Scrip